Latest news with #PetMed
Business Upturn
15-07-2025
- Business
- Business Upturn
Bragar Eagel & Squire, P.C Continues Investigations on Behalf of PetMed, GeneDx, Lineage, and Proficient Auto and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS), GeneDx (WGS), Lineage (LINE), or Proficient Auto (PAL) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PetMed (PETS), GeneDx (WGS), Lineage (LINE), and Proficient Auto (PAL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. PetMed Express, Inc. (NASDAQ: PETS) On June 10, 2025, PetMed issued a press release 'announc[ing] it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process.' On this news, PetMed's stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025. For more information on the SelectQuote investigation go to: GeneDx Holdings Corp. (NASDAQ:WGS) On February 5, 2025, Grizzly Research ('Grizzly') published a report entitled 'Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud'. The Grizzly report asserted, among other things, that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue'; that '[t]estimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as 'code stacking'', which 'enables the company to bill insurance providers for services that do not meet the required criteria'; and that 'CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases', a 'pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company.' On this news, GeneDx's stock price fell $4.84 per share, or 6.72%, to close at $67.18 per share on February 5, 2025. For more information on the Cleveland-Cliffs investigation go to: Lineage, Inc. (NASDAQ:LINE) On April 30, 2025, Lineage reported first quarter 2025 financial results, including that '[t]otal revenue decreased (2.7)%' to $1.29 billion for the quarter. The Company stated it 'experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.' On this news, Lineage's stock price fell $8.26, or 14.62%, to close at $48.23 per share on April 30, 2025, thereby injuring investors. For more information on the Lineage investigation go to: Proficient Auto Logistics, Inc. (NASDAQ:PAL) On May 7, 2025, Proficient Auto announced financial results for its first quarter ended March 31, 2025, revealing that the Company had suffered a 0.4% year-over-year decrease in total operating revenue to $95.2 million and total operating loss of $2.4 million during the quarter. On this news, Proficient Auto's stock price fell $0.40 per share, or 4.93%, to close at $7.72 per share on May 8, 2025. For more information on the Semler investigation go to: About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Esq. Marion Passmore, Esq.(212) 355-4648 [email protected]
Business Wire
26-06-2025
- Business
- Business Wire
Securities Fraud Investigation Into PetMed Express, Inc. (PETS) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of PetMed Express, Inc. ('PetMed' or the 'Company') (NASDAQ: PETS) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PETMED EXPRESS, INC. (PETS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On June 10, 2025, PetMed disclosed that it would be delaying the release of its fourth quarter and fiscal year 2025 financial results because it 'requires additional time to complete the year-end audit process." On this news, PetMed's stock price fell $0.47, or 11.2%, to close at $3.72 per share on June 11, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding PetMed should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
